Search Results - "Spirli, Alessia"

Effect of Roscovitine on Intracellular Calcium Dynamics: Differential Enantioselective Responses by Tamma, Grazia, Ranieri, Marianna, Di Mise, Annarita, Spirlì, Alessia, Russo, Annamaria, Svelto, Maria, Valenti, Giovanna

“…Cyclin-dependent kinases (CDKs) inhibitors have emerged as interesting therapeutic candidates. Of these, (S)-roscovitine has been proposed as potential…”
Get full text

P868: MEZIGDOMIDE (MEZI) PLUS DEXAMETHASONE (DEX) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS FROM THE DOSE‐EXPANSION PHASE OF THE CC‐92480‐MM‐001 TRIAL by Bahlis, Nizar J, Trudel, Suzanne, Quach, Hang, Popat, Rakesh, Lonial, Sagar, Orlowski, Robert Z, Kim, Kihyun, Mateos, Maria‐Victoria, Pawlyn, Charlotte, Ramasamy, Karthik, Martinez‐Lopez, Joaquín, Casas‐Avilés, Ignacio, Spirli, Alessia, Gong, Jing, Amatangelo, Michael, Katz, Jessica, Maciag, Paulo, Peluso, Teresa, Richardson, Paul

Get full text

The serine‐threonine kinase PIM3 is an aldosterone‐regulated protein in the distal nephron by Spirli, Alessia, Cheval, Lydie, Debonneville, Anne, Penton, David, Ronzaud, Caroline, Maillard, Marc, Doucet, Alain, Loffing, Johannes, Staub, Olivier

“…The mineralocorticoid hormone aldosterone plays a crucial role in the control of Na+ and K+ balance, blood volume, and arterial blood pressure, by acting in…”
Get full text

WNK3 abrogates the NEDD4-2-mediated inhibition of the renal Na+-Cl- cotransporter by Lagnaz, Dagmara, Arroyo, Juan Pablo, Chávez-Canales, María, Vázquez, Norma, Rizzo, Federica, Spirlí, Alessia, Debonneville, Anne, Staub, Olivier, Gamba, Gerardo

“…The serine/threonine kinase WNK3 and the ubiquitin-protein ligase NEDD4-2 are key regulators of the thiazide-sensitive Na+-Cl- cotransporter (NCC), WNK3 as an…”
Get more information

Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma by Richardson, Paul G., Trudel, Suzanne, Popat, Rakesh, Mateos, María-Victoria, Vangsted, Annette J., Ramasamy, Karthik, Martinez-Lopez, Joaquín, Quach, Hang, Orlowski, Robert Z., Arnao, Mario, Lonial, Sagar, Karanes, Chatchada, Pawlyn, Charlotte, Kim, Kihyun, Oriol, Albert, Berdeja, Jesus G., Rodríguez Otero, Paula, Casas-Avilés, Ignacio, Spirli, Alessia, Poon, Jennifer, Li, Shaoyi, Gong, Jing, Wong, Lilly, Lamba, Manisha, Pierce, Daniel W., Amatangelo, Michael, Peluso, Teresa, Maciag, Paulo, Katz, Jessica, Pourdehnad, Michael, Bahlis, Nizar J.

“…Oral mezigdomide is a cereblon-modifying agent that results in degradation of transcription factors essential for myeloma cell survival. Given with…”
Get full text

Renal Salt and Water Homeostasis: a New Regulatory Pathway Involving the Ser/Thr Kinase PIM‐3 by Spirli, Alessia, Ronzaud, Caroline, Debonneville, Anne, Staub, Olivier

“…Abstract only Since many years now, scientists believe that a great credit for the blood pressure regulation goes to the kidneys, as their inability in…”
Get full text

Mezigdomide (CC-92480), a Potent, Novel Cereblon E3 Ligase Modulator (CELMoD), Combined with Dexamethasone (DEX) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results from the Dose-Expansion Phase of the CC-92480-MM-001 Trial by Richardson, Paul G., Trudel, Suzanne, Quach, Hang, Popat, Rakesh, Lonial, Sagar, Orlowski, Robert Z., Kim, Kihyun, Mateos, María-Victoria, Pawlyn, Charlotte, Ramasamy, Karthik, Martinez-Lopez, Joaquín, Spirli, Alessia, Casas-Avilés, Ignacio, Gong, Jing, Amatangelo, Michael, Katz, Jessica, Maciag, Paulo, Peluso, Teresa, Bahlis, Nizar J.

Get full text

P-265 Mezigdomide (MEZI) monotherapy in relapsed/ refractory multiple myeloma (RRMM): results from the CC-92480-MM-001 trial by Goldsmith, Scott, Oriol, Albert, Anttila, Pekka, Bahlis, Nizar, Berdeja, Jesus, Cowan, Andrew, Dimopoulos, Meletios, Foster, Laahn, Hillengass, Jens, Louzada, Martha, Wu, Ka Lung, Chow, Tracy, Chen, Wencong, Wang, Yue, Spirli, Alessia, Koo, Phillip, Maciag, Paulo, Zhu, Daniel, Katz, Jessica, Richardson, Paul

Get full text

POSTER: MM-360 Mezigdomide (MEZI) Plus Dexamethasone (DEX) in Relapsed/Refractory Multiple Myeloma (RRMM): Results From the Dose-Expansion Phase of the CC-92480-MM-001 Trial by Orlowski, Robert Z., Bahlis, Nizar J., Quach, Hang, Popat, Rakesh, Lonial, Sagar, Kim, Kihyun, Mateos, María-Victoria, Pawlyn, Charlotte, Ramasamy, Karthik, Martínez-Lopez, Joaquín, Casas-Avilés, Ignacio, Spirlì, Alessia, Gong, Jing, Amatangelo, Michael, Katz, Jessica, Maciag, Paulo, Peluso, Teresa, Richardson, Paul G., Trudel, Suzanne

Get full text

MM-360 Mezigdomide (MEZI) Plus Dexamethasone (DEX) in Relapsed/refractory Multiple Myeloma (RRMM): Results From the Dose-Expansion Phase of the CC-92480-MM-001 Trial by Orlowski, Robert Z., Bahlis, Nizar J., Quach, Hang, Popat, Rakesh, Lonial, Sagar, Kim, Kihyun, Mateos, María-Victoria, Pawlyn, Charlotte, Ramasamy, Karthik, Martínez-Lopez, Joaquín, Casas-Avilés, Ignacio, Spirlì, Alessia, Gong, Jing, Amatangelo, Michael, Katz, Jessica, Maciag, Paulo, Peluso, Teresa, Richardson, Paul G., Trudel, Suzanne

“…MEZI is a novel, potent oral cereblon E3 ligase modulator (CELMoD™) with enhanced antimyeloma effects compared with immunomodulatory drugs (IMiDs®). In…”
Get full text